BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Biotech Holdings Ltd. (BIOHF) Revenues Grow Compared to Earlier Quarters


5/15/2007 1:50:41 PM

VANCOUVER, May 15 /PRNewswire-FirstCall/ - Biotech Holdings reports that sales of its Sucanon diabetes drug for the quarter ended March 31, 2007 were $150,761. This was an increase of $23,567 or about 18.5% over the revenues of the quarter ending December 31, 2006 and an increase of $122,526 or approximately 400% over revenues of $28,235 in the year-earlier quarter ending March 31, 2006.

The quarter ended March 31, 2007 was the second consecutive quarter of sales growth. To support this growth, the Company added an additional manager to its Mexico City office in January, 2007.

All figures are subject to confirmation in the issuance of the Company's audited annual financial statements, including the March 31, 2007 quarter, which are projected to be made available and filed to sedar.com in the Company's second fiscal quarter, ending September 30, 2007.

For further information, contact Austin Rand at Biotech Holdings, 1 888 216 111 (toll-free) 8a.m. to 4 p.m. Pacific time. For background information on Biotech Holdings, or to receive news updates, see www.biotechltd.com.

This release has been approved by the Board of Directors of Biotech Holdings. Directors of the Company can be reached through the Company's main telephone number, 604 295 1119.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release. Robert B. Rieveley, Pres. On behalf of the Board of Directors

Any statements made in this release that are not based on historical fact are forward-looking statements. Any forward-looking statements made in this release represent management's best judgement as to what may occur in the future. However, actual outcome and results are not guaranteed and are subject to certain risks, uncertainties and assumptions and may differ materially from what is expressed.

CONTACT: Austin Rand at Biotech Holdings, 1-888-216-111 (toll-free)

Biotech Holdings Ltd.

CONTACT: Austin Rand at Biotech Holdings, 1-888-216-111 (toll-free)



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES